Searched for
BIOSIMILAR
Biocon arm gets Japan nod for cancer drug pegfilgrastim biosimilarIn a significant advancement, Biocon Biologics has gained marketing approval for its pegfilgrastim biosimilar in Japan. This vital cancer s...- Jefferies initiates coverage on Anthem Biosciences with a Rs 1,050 targetJefferies has initiated coverage on Anthem Biosciences with a Buy rating and Rs 1,050 target, implying around 20% upside. The brokerage is ...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsHere’s one thing to watch for in the next few weeks: How does the street treat disappointments in the mid-cap segment? If the reaction is l...
- India's pharma sector must shift from cost competitiveness to innovation, global quality: ExpertsFor the growth of India's pharmaceutical sector, prioritizing innovation and advanced manufacturing is essential. Experts indicate that inc...
- Biocon shares rise 2% after USFDA approval for Yesintek single-dose prefilled autoinjectorBiocon shares rose after its US subsidiary received supplemental FDA approval for Yesintek single-dose prefilled autoinjectors in two stren...
- Thermo Fisher finds India the perfect lab; lab equipment maker steps up investments as drug companies focus on innovationThermo Fisher Scientific is amplifying its investment footprint in India, driven by the strong anticipated growth in the biosimilars and in...
- Drug formulations & biologicals keep India's pharma exports healthy in Q1During the first quarter of fiscal 2027, India's pharmaceutical exports soared to $8.10 billion, showcasing remarkable strength in drug for...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsWhat is volatility? There is, of course, a mathematical definition. Then there is the human definition, which is how investors feel it. In ...
- Zydus Lifesciences Q1 Results: Net profit down 36% at Rs 939.8 croreZydus Lifesciences reported a significant year-on-year decline of thirty-six percent in net profit for the first quarter, despite a robust ...
- Independence Day 2026: India, which once couldn't make smallpox vaccine, has now crossed a pharma milestone the world can't ignore2026 Independence Day: India's pharmaceutical industry marks a historic milestone with a new drug approval. This achievement reflects decad...
- Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsA word of caution for all those who have exposure to mid cap stocks or are planning to increase it. Just keep one thing in mind: If there i...
- India Inc goes on a global shopping spree with a new wishlistIndian companies are increasingly pursuing strategic overseas acquisitions. They now focus on acquiring capabilities and technology rather ...
- ET Health Conclave 2026: Healthcare leaders reimagine the future of medicine through innovation, prevention and technologyThe ET Health Conclave 2026 celebrated healthcare professionals and institutions. Leaders shared insights on healthcare infrastructure and ...
- India pharma sector to miss 2030 sales target amid tariff and shipping woes, trade body saysIndia's pharmaceutical industry is expected to reach$80-90 billion by 2030, well below its earlier$130 billion target, as U.S. tariff uncer...
- Buy, Sell or Hold: Goldman Sachs maintains buy rating on Jindal Stainless; Citi recommends sell call on BioconIGI: Morgan Stanley stays bullish, citing strong certification-market growth and the company’s shift toward a consumer-focused business.Jin...
- Biocon gets Health Canada nod for Yesintek autoinjector penBiocon received Health Canada approval for its Yesintek autoinjector. This new format offers patients a convenient treatment option for pso...
- Tariff on generic drugs: Loud announcement, little consequence? 7 pharma stocks with upside potential of up to 31%The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...
- US market drag keeps Dr Reddy's, Cipla under pressure despite strong product pipelineIndian pharmaceutical firms experienced a challenging June quarter, marked by declining US business profits. Dr Reddy's and Cipla saw signi...
- Domestic formulations, chronic therapies to drive Pharma Q1; US generics remain dragThe healthcare sector anticipates strong growth in domestic formulations and emerging markets. Companies with less US generics dependence w...
Load More
